Tokyo Tanabe Sales Above Expectations
Tokyo Tanabe achieved sales in the first six months of the 1994/95 fiscal year of 18.3 billion yen ($182.1 million), up 10.5%. The progress was said to have been driven by sales of Anplag (sarpogrelate HCl), which amounted to 2.4 million yen. Tokyo Tanabe acquired the product from Mitsubishi Chemical. Profits at the company were also said to have increased.
The company spent 1.7 billion yen on R&D in the period from April to September, which represents 9.3% of sales. This figure is expected to rise to around 3.7 billion yen for the full year, according to Pharma Japan.
The company has indicated that it intends to acquire a site in the Chiba Prefecture Kazusa Academia Park in the new year. It will construct new laboratories there which should be operational some time next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze